EGFR+ Lung Cancer

Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

A statistically significant overall survival benefit was not observed with osimertinib compared with platinum-pemetrexed therapy as treatment of patients with EGFR T790M-mutated advanced non–small cell lung cancer.

The benefits and risks of osimertinib as second- or later-line treatment of patients with EGFR-positive non–small cell lung cancer that were reported when the agent was first approved, have now been confirmed, according to data from a real-world study conducted in Japan.

Sequential afatinib followed by osimertinib led to encouraging outcomes in patients with deletion 19 (del19) or L858R epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer, according to the final analysis results from the real-world study, GioTag.

Experts in lung oncology review 3 clinical cases and discuss individualized treatment approaches for each patient.

This is the first report to date that has demonstrated inferior survival outcomes among African American patients with NSCLC harboring an EGFR mutation relative to non-African American patients.